Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Evans

Showing results (591-600 of 621) with videos related to

Pageof 63
Sort By:
Cancers|March 25, 2022
Familial Aspects of Mammographic Density Measures Associated with Breast Cancer RiskTuong L Nguyen, Shuai Li, James G Dowty, et al.
Cancers|June 10, 2022
Genetic Aspects of Mammographic Density Measures Associated with Breast Cancer RiskShuai Li, Tuong L Nguyen, Tu Nguyen-Dumont, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 15, 2009
Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammationDaniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 17, 2008
The nuclear membrane organization of leukotriene synthesisAsim K Mandal, Phillip B Jones, Angela M Bair, et al.
Nature Medicine|August 24, 2004
The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysmLei Zhao, Michael P W Moos, Rolf Gräbner, et al.
Rheumatology (Oxford, England)|September 29, 1999
Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2P Brooks, P Emery, J F Evans, et al.
British Journal of Pharmacology|July 24, 2010
A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin modelJ S Swaney, C Chapman, L D Correa, et al.
Breast Cancer Research : BCR|December 15, 2018
Predicting interval and screen-detected breast cancers from mammographic density defined by different brightness thresholdsTuong L Nguyen, Ye K Aung, Shuai Li, et al.
Bioorganic & Medicinal Chemistry Letters|January 8, 2011
Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonistNicholas Stock, Deborah Volkots, Karin Stebbins, et al.
The Journal of Biological Chemistry|March 13, 1999
Identification of a GABAB receptor subunit, gb2, required for functional GABAB receptor activityG Y Ng, J Clark, N Coulombe, et al.
Pageof 63

Showing results (591-600 of 621) with videos related to

Sort By:
Pageof 63
Cancers|March 25, 2022
Familial Aspects of Mammographic Density Measures Associated with Breast Cancer RiskTuong L Nguyen, Shuai Li, James G Dowty, et al.
Cancers|June 10, 2022
Genetic Aspects of Mammographic Density Measures Associated with Breast Cancer RiskShuai Li, Tuong L Nguyen, Tu Nguyen-Dumont, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 15, 2009
Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammationDaniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 17, 2008
The nuclear membrane organization of leukotriene synthesisAsim K Mandal, Phillip B Jones, Angela M Bair, et al.
Nature Medicine|August 24, 2004
The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysmLei Zhao, Michael P W Moos, Rolf Gräbner, et al.
Rheumatology (Oxford, England)|September 29, 1999
Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2P Brooks, P Emery, J F Evans, et al.
British Journal of Pharmacology|July 24, 2010
A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin modelJ S Swaney, C Chapman, L D Correa, et al.
Breast Cancer Research : BCR|December 15, 2018
Predicting interval and screen-detected breast cancers from mammographic density defined by different brightness thresholdsTuong L Nguyen, Ye K Aung, Shuai Li, et al.
Bioorganic & Medicinal Chemistry Letters|January 8, 2011
Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonistNicholas Stock, Deborah Volkots, Karin Stebbins, et al.
The Journal of Biological Chemistry|March 13, 1999
Identification of a GABAB receptor subunit, gb2, required for functional GABAB receptor activityG Y Ng, J Clark, N Coulombe, et al.
Pageof 63